Background: Myeloproliferative Neoplasm (MPN) is a clonal disorder of blood progenitor cells during haematopoiesis. JAK2V617F mutation represents one of the major identified genetic reasons of MPN disorder. It has been shown that JAK2V617F zygosity is associated with disease phenotype. However, studies showed variable findings regarding individual phenotype parameters and significance of effect.
Objectives: the aim of this study was to determine frequency of JAK2V617F zygosity and corresponding outcomes in this population.
Methods: This cross-section study recruited JAK2V617F-mutated polycythemia Vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) patients. DNA samples were extracted from peripheral blood and JAK2V617F zygosity was determined using ARMS-PCR method.
Results: A total of 162 patients (91 males and 71 females) were analysed. Of total, 131 (80.86 %) were heterozygous and 31 (19.14 %) were homozygous for JAK2V617F. homozygous characterized with higher age (P= 0.0153) and WBC count (P= < 0.0001). Among total MPN cases, the number of PV, ET, and MF patients was 102 (62.96%), 37 (22.84%), and 23 (14.2%) respectively. The frequency of homozygous cases was 20.6 %, 10.8 %, and 26.1 % for PV, ET, and MF patients respectively. No significant difference seen in age, BMI, and HCT between homozygous and heterozygous cases in all MPN groups. In ET group, homozygous patients showed significant HGB reduction (P= 0.0186) and PLT increase (P= 0.0034) compared with heterozygous patients. WBC count in homozygous patients was significantly higher than heterozygous in PV (P= 0.0071), ET (P= <0.0001), and MF (P= 0.07) patients.
Conclusion: JAK2V617F zygosity is useful marker in determining disease severity and can be used for prediction of prognosis in MPN patients. ARMS-PCR is simple, easy, and useful technique in determining zygosity of mutations and does not need to advanced laboratory resources. We recommend including zygosity in laboratory reports when conducting JAK2V617F using ARMS-PCR technique.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.31557/APJCP.2025.26.2.677 | DOI Listing |
Asian Pac J Cancer Prev
February 2025
Department of Molecular Biology, The National Center of Hematology, Mustansiriyah University, Baghdad 10015, Iraq.
Background: Myeloproliferative Neoplasm (MPN) is a clonal disorder of blood progenitor cells during haematopoiesis. JAK2V617F mutation represents one of the major identified genetic reasons of MPN disorder. It has been shown that JAK2V617F zygosity is associated with disease phenotype.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
February 2021
Department of Statistics, Liaquat National Hospital and Medical College, Karachi, Pakistan.
Background: Estimation of JAK2V617F mutational load in Polycythemia Vera (PV) helps to determine the severity of the disease phenotype, the risk of thrombotic events, progression to post-PV myelofibrosis and survival. Amplification Refractory Mutation Screening (ARMS) PCR or Allele Specific (AS) PCR is a simple easy method with a reasonable sensitivity for screening of zygosity.The purpose of this study was to see the frequency of disease burden and phenotypic characteristics in Pakistani patients diagnosed with JAK2V617F mutation positive PV.
View Article and Find Full Text PDFAm J Surg Pathol
June 2008
III Department of Internal Medicine, Klinikum rechts der Isar, Munich, Germany.
The JAK2V617F mutation is an essential oncogenic event in Philadelphia negative chronic myeloproliferative disorders (Ph-cMPD). It is still unclear how a unique tyrosine kinase mutation can give rise to the broad clinical and morphologic spectrum of Ph-cMPD. One possible explanation could be differences in the JAK2V617F gene dosage, or different maturation stages on which myeloid lineages are affected by the mutation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!